Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
A phase II clinical trial designed to test the effect of combining endocrinal therapy
(Letrozole) with chemotherapy (Capecitabine) in first line treatment of advanced cases of
female breast cancer with ER positive disease.